echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Janssen's potential "first-in-class" dual-antibody therapy starts clinical trials in China

    Janssen's potential "first-in-class" dual-antibody therapy starts clinical trials in China

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    China's drug clinical trial registration and information disclosure platform shows that the Johnson & Johnson's Janssen's new class 1 drug, talentamab injection, has initiated a phase 2 treatment for relapsed or refractory multiple myeloma (MM) Clinical research


    Screenshot source: Chinadrugtrials

    GPRC5D (G protein coupled receptor C5 family subtype D) is an innovative multiple myeloma target, which is highly expressed in multiple myeloma cells and is associated with poor prognostic factors


    According to the Chinese Drug Clinical Trial Registration and Information Disclosure Platform website, the launch in China this time is a project carried out in subjects with relapsed or refractory multiple myeloma, about the 1/2 phase of talentamab and its first use in humans.


    It is worth mentioning that at the 2020 American Society of Hematology (ASH) annual meeting, Janssen Company has announced the results of early clinical trials of valvetamab in the treatment of multiple myeloma patients.


    At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Janssen once again announced the follow-up data of the first phase 1 human dose escalation study (MonumenTAL-1) of talentamab


    These efficacy and safety data indicate that talentamab is a promising treatment candidate for patients with multiple myeloma who have relapsed after multiple treatments or have not responded to other treatments


    Reference materials:

    [1] Drug clinical trial registration and information disclosure platform.


    [3] Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.